Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals, Inc. (AMLX) has a notice filed on behalf of officer Gina Mazzariello for the potential sale of 21,284 shares of common stock under Rule 144 in connection with the vesting of performance-based restricted stock units on September 10, 2026. The shares represent amounts required to be sold to cover tax withholding obligations, and the filing states the sales were automatic and not at her discretion. In the prior three months, she reported sales totaling 30,000 shares of common stock for the same person.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Joshua B. Cohen filed a notice to sell shares of the company’s common stock under Rule 144.
The planned sale covers 60,039 shares of common stock on September 10, 2026, arising from the vesting of performance-based restricted stock units. According to the notice, the shares are being sold to satisfy tax withholding obligations related to that vesting and the sales were described as automatic and not at Cohen’s discretion.
Amylyx Pharmaceuticals, Inc. (AMLX) announced long-term manufacturing arrangements for its avexitide drug substance, contingent on regulatory approval. On September 8, 2026, the company entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc., and on September 1, 2026, it signed a term sheet with Polypeptide Group AG for similar supply.
Beginning in 2028, Amylyx has agreed, under both arrangements, to purchase a minimum annual quantity of avexitide at agreed supply prices, with periodic forecasts of demand that are partially binding. The Bachem agreement includes annual price adjustments effective each January 1 and requires Amylyx to pay certain maintenance fees and expenses. It has a five-year initial term and automatically renews for successive three-year periods unless terminated for reasons such as material breach, bankruptcy, insolvency, or certain regulatory actions.
Under the Polypeptide term sheet, Amylyx will pay a $30 million upfront fee for capacity reservation and related commitments and plans to finalize a definitive Polypeptide Manufacturing Agreement with fixed volume-based pricing, subject to annual adjustment. Both Bachem and Polypeptide will act as non-exclusive suppliers, and Amylyx may use additional manufacturers.
Amylyx Pharmaceuticals, Inc. (AMLX) director Karen Firestone reported exercising stock options to acquire common shares on August 31, 2026. She exercised two fully vested stock option grants covering a total of 50,000 shares of Common Stock, at exercise prices of $1.76 and $5.05 per share, respectively. The filing does not show her post-transaction share balances, and no Rule 10b5-1 trading plan is reported.
Amylyx Pharmaceuticals, Inc. (symbol: AMLX) is the issuer of record for a Form 4 filing submitted to the SEC.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Justin B. Klee acquired 60,039 shares of Common Stock on August 18, 2026 through a grant classified as a performance-based award. The shares are represented by performance share units that vested on that date. Following this award, Klee directly holds 3,643,520 shares of Amylyx Pharmaceuticals Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Legal Officer Gina Mazzariello acquired additional equity-based compensation. On August 18, 2026, she received 21,284 shares of Common Stock represented by performance share units (PSUs) that were awarded upon the achievement of certain performance metrics and vested on that date. Following this award, she directly holds 200,374 shares of Amylyx Pharmaceuticals common stock.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Chief Medical Officer Camille L. Bedrosian acquired 22,807 shares of common stock through a compensation-related grant. The shares are represented by performance share units (PSUs) that were awarded upon achievement of specified performance metrics and vested on August 18, 2026. Following this vesting, Bedrosian holds 288,092 common shares directly.
Amylyx Pharmaceuticals, Inc. (AMLX) reported that Co-Chief Executive Officer and director Joshua B. Cohen received an equity award linked to company performance. On August 18, 2026, he acquired 60,039 shares of Common Stock represented by performance share units (PSUs) that vested on that date upon achievement of specified performance metrics. Following this vesting event, Cohen directly holds 3,643,587 shares of Amylyx Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) announced an underwritten public offering of 14,090,000 shares of common stock at $35.50 per share, with underwriters granted a 30-day option to purchase up to an additional 2,113,500 shares at the public price less underwriting discounts and commissions.
Amylyx expects to receive aggregate net proceeds of approximately $471.7 million, or approximately $542.5 million if the option is fully exercised. The company intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund the potential U.S. commercial launch of avexitide, if approved, including additional manufacturing capacity, and for research and development, working capital and other general corporate purposes. The offering is expected to close on August 21, 2026, subject to customary closing conditions.